- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00922506
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study"
OAB occurs in approximately 50% to 75% of men with BPO and up to 38% of men with BPO continue to suffer from OAB after relief the obstruction.Symptoms of OAB are more bothersome than the voiding complaints of slow stream and hesitancy. However, the patients with both BPO and OAB are often not treated with muscarinic receptor antagonists due to concern that they will experience acute urinary retention.
Tolterodine is a potent and pure muscarinic receptor antagonist that was developed specifically for the treatment of overactive bladder. Recently, studies revealed that tolterodine was effective, safe and well tolerated in adults with OAB and urodynamically confirmed BPO.However, the optimal dosage of antimuscarinic for the treatment of OAB coexisting BPO was not yet fully assessed. In real clinical situation, some patients complain voiding difficulty after addition of antimuscarinics and want to stop antimuscarinics.It is probable that a lower dosage of antimuscarinics combined with alpha-adrenergic antagonists can be used safely in OAB patients with BOO, with the same efficacy.
This study is designed to investigate the optimal doses of tolterodine SR in combination with doxazosin in men with both BOO and OAB based on efficacy, safety, and tolerability.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male aged 50 ≤ and ≤ 80 years
- Proven bladder outlet obstruction (BOO, Abrams/Griffith score >20) on urodynamic study
Symptoms of OAB as verified by the 3 day voiding diary, defined by:
- symptoms of urinary urgency (defined as a level of ≥3 in a 5 point urgency scale) at least two episode per 24 hours and
- symptoms of urinary frequency (8 micturitions per 24 hours)
- Total International Prostate Symptom Score (IPSS) of 12 or higher
- IPSS quality-of-life (QOL) item score of 3 or higher
- A rating of the bladder condition at Baseline prior to randomization as "Some Moderate Problems", "Severe Problems", or "Many Severe Problems" on the Patient Perception of Bladder Condition (PPBC) questionnaire.
- Ability and willingness to correctly complete the micturition diary and questionnaire
- Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits
Exclusion Criteria:
- Patients have a baseline post-void residual (PVR) which exceeded 150 mL.
- Any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrow-angled glaucoma, urinary retention or gastric retention.
- Symptomatic acute urinary tract infection (UTI) during the screening period.
- Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with any anticholinergic drugs and drug treatment for overactive bladder.
- A 5-alpha reductase inhibitor if started less than 3 months prior to screening.
- Patients with previous urethral, prostate or bladder neck surgery.
- Patients with cancer of any type including cancer of the prostate or bladder, uncontrolled medical condition including psychiatric disease or life threatening illness.
- Patients with Parkinson's disease, stroke, multiple sclerosis, spinal cord disease.
- Patients with suspected neurogenic bladder disorder.
- Patients with urethral stricture or bladder neck contracture.
- Serum PSA 4ng/ml (only patients with no malignancy by prostate biopsy can be included).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: doxazosin plus tolterodine SR 2 mg
doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
|
doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
Other Names:
|
Experimental: doxazosin plus tolterodine SR 4 mg
doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
|
doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Numeric change of urgency episodes per 24 hours
Time Frame: 12 weeks of treatment
|
12 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in voiding diary parameters
Time Frame: 12 weeks of treatment
|
12 weeks of treatment
|
Change in symptom questionnaires
Time Frame: 12 weeks
|
12 weeks
|
Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue
Time Frame: 12 weeks
|
12 weeks
|
Change of uroflowmetry and PVR
Time Frame: 12 weeks
|
12 weeks
|
Incidence of acute urinary retention
Time Frame: during all study periods
|
during all study periods
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Prostatic Diseases
- Urinary Bladder, Overactive
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Doxazosin
- Tolterodine Tartrate
Other Study ID Numbers
- 2008-08-092
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on doxazosin plus tolterodine SR
-
Dr .S.B.PATANKARCompleted
-
Far Eastern Memorial HospitalNational Science Council, TaiwanCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...PfizerCompletedUrinary Incontinence
-
Antonios LikourezosTerminatedAttention Deficit Hyperactivity DisorderUnited States
-
Buddhist Tzu Chi General HospitalCompletedBladder Outlet ObstructionTaiwan
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveChina, Taiwan, India, Korea, Republic of
-
Bern University of Applied SciencesCompletedMuscle Weakness | Poor Performance StatusSwitzerland
-
Buddhist Tzu Chi General HospitalCompletedBenign Prostatic HyperplasiaTaiwan
-
Orexigen Therapeutics, IncTerminatedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisorderUnited States
-
University of California, San FranciscoCompletedKidney DiseaseUnited States